prilocaine has been researched along with Sensation Disorders in 5 studies
Prilocaine: A local anesthetic that is similar pharmacologically to LIDOCAINE. Currently, it is used most often for infiltration anesthesia in dentistry.
prilocaine : An amino acid amide in which N-propyl-DL-alanine and 2-methylaniline have combined to form the amide bond; used as a local anaesthetic.
Sensation Disorders: Disorders of the special senses (i.e., VISION; HEARING; TASTE; and SMELL) or somatosensory system (i.e., afferent components of the PERIPHERAL NERVOUS SYSTEM).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The study included data sets of annual sales of local anesthetics (from 1995 through 2007), 292 reports to the Danish Medicines Agency, Copenhagen, Denmark, of adverse reactions to local anesthetic drugs, and a clinical sample of 115 patients with NSD associated with local anesthetics." | 1.37 | Trigeminal nerve injury associated with injection of local anesthetics: needle lesion or neurotoxicity? ( Ersbøll, BK; Hillerup, S; Jensen, RH, 2011) |
| "The 34 percent [corrected] incidence of dysesthesia in the patients in this study is of concern." | 1.31 | Permanent nerve involvement resulting from inferior alveolar nerve blocks. ( Pogrel, MA; Thamby, S, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hillerup, S | 1 |
| Jensen, RH | 1 |
| Ersbøll, BK | 1 |
| Henry, R | 1 |
| Morales, A | 1 |
| Rosén, B | 1 |
| Björkman, A | 1 |
| Lundborg, G | 1 |
| Pogrel, MA | 2 |
| Bryan, J | 1 |
| Regezi, J | 1 |
| Thamby, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Is the Direct Inferior Alveolar Nerve Block Required for Third Lower Molar Extraction?[NCT03443726] | 120 participants (Actual) | Interventional | 2017-06-10 | Completed | |||
| A Phase IIb, Multi-center, Randomized, Double-blind, Placebo-controlled Study, With Open-label Follow on, to Evaluate the Efficacy, Safety and Tolerability of PSD502 in Subjects With Premature Ejaculation (PE)[NCT00556478] | Phase 2/Phase 3 | 256 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Summary of mean IELT at Baseline and at month 3 during double-blind treatment (NCT00556478)
Timeframe: 3 months
| Intervention | Seconds (Geometric Mean) |
|---|---|
| Double-Blind Active / Open-Label Active | 140.964 |
| Double-Blind Placebo / Open-Label Active | 49.615 |
"To evaluate efficacy of treatment with PSD502 compared with placebo in subjects with PE as measured by:~• change in mean IELT from baseline to during the 3 month double-blind treatment~Results provide are ratio (over the 3 months/baseline)." (NCT00556478)
Timeframe: Baseline to 3 Months
| Intervention | ratio (Geometric Mean) |
|---|---|
| Double-Blind Active / Open-Label Active | 4.607 |
| Double-Blind Placebo / Open-Label Active | 1.505 |
"Change in the IPE domains of ejaculatory control, distress and sexual satisfaction from Baseline to month 1.~Ejaculatory control scores range from 4 to 20 with a higher score indicating greater ejaculatory control Sexual satisfaction scores range from 4 to 20 with a higher score indicating greater sexual satisfaction Distress scores range from 2 to 10 with a higher score indicating less distress" (NCT00556478)
Timeframe: 1 month
| Intervention | Score (Mean) | ||
|---|---|---|---|
| Ejaculatory control | Distress | Sexual satisfaction | |
| Double-Blind Active / Open-Label Active | 5.7 | 2.5 | 5.1 |
| Double-Blind Placebo / Open-Label Active | 1.3 | 0.6 | 1.8 |
"Change in the IPE domains of ejaculatory control, distress and sexual satisfaction from Baseline to month 2~Ejaculatory control scores range from 4 to 20 with a higher score indicating greater ejaculatory control Sexual satisfaction scores range from 4 to 20 with a higher score indicating greater sexual satisfaction Distress scores range from 2 to 10 with a higher score indicating less distress" (NCT00556478)
Timeframe: 2 months
| Intervention | Score (Mean) | ||
|---|---|---|---|
| Control | Satisfaction | Distress | |
| Double-Blind Active / Open-Label Active | 6.5 | 5.8 | 2.9 |
| Double-Blind Placebo / Open-Label Active | 1.4 | 1.3 | 0.7 |
"To Evaluate Efficacy of Treatment With PSD502 Compared With Placebo in Subjects With PE as measured by:~• changes in all 3 IPE domains from baseline to month 3~Ejaculatory control scores range from 4 to 20 with a higher score indicating greater ejaculatory control Sexual satisfaction scores range from 4 to 20 with a higher score indicating greater sexual satisfaction Distress scores range from 2 to 10 with a higher score indicating less distress" (NCT00556478)
Timeframe: Baseline to 3 Months
| Intervention | Score (Mean) | ||
|---|---|---|---|
| Ejaculatory control | Sexual satisfaction | Distress | |
| Double-Blind Active / Open-Label Active | 7.2 | 6.6 | 3.5 |
| Double-Blind Placebo / Open-Label Active | 2.2 | 2.1 | 0.9 |
Scores for perceived control over ejaculation, personal distress related to ejaculation, satisfaction with sexual intercourse and interpersonal difficulty related to ejaculation based on the partner PEP at month 3. Proportion of partners with at least a 1 point category improvement in partner PEP domain scores from baseline to month 3. (NCT00556478)
Timeframe: 3 months
| Intervention | percentage of partners (Number) | |||
|---|---|---|---|---|
| Control | Distress | Sexual satisfaction | Interpersonal difficulty | |
| Double-Blind Active / Open-Label Active | 68.9 | 64.9 | 62.8 | 66.9 |
| Double-Blind Placebo / Open-Label Active | 40.8 | 50.0 | 32.9 | 50.0 |
Percentage of subjects with mean IELT > 1 minute and >2 minutes during the 3 months of double-blind treatment as measured by the proportion of subjects (NCT00556478)
Timeframe: 3 months
| Intervention | percentage of subjects (Number) | |
|---|---|---|
| IELT > 1 minute | IELT > 2 minutes | |
| Double-Blind Active / Open-Label Active | 80.2 | 57.5 |
| Double-Blind Placebo / Open-Label Active | 37.8 | 14.6 |
Scores for perceived control over ejaculation, personal distress related to ejaculation, satisfaction with sexual intercourse and interpersonal difficulty related to ejaculation based on the subject PEP at month 1. Percentage of subjects with at least a 1 point category improvement in subject PEP domain scores at month 1. (NCT00556478)
Timeframe: 1 month
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Control | Distress | Sexual satisfaction | Interpersonal difficulty | |
| Double-Blind Active / Open-Label Active | 59.6 | 63.4 | 62.7 | 72.0 |
| Double-Blind Placebo / Open-Label Active | 23.5 | 27.2 | 33.3 | 51.9 |
Scores for perceived control over ejaculation, personal distress related to ejaculation, satisfaction with sexual intercourse and interpersonal difficulty related to ejaculation based on the subject PEP at month 2. Proportion of subjects with at least a 1 point category improvement in subject PEP domain scores from baseline to month 2. (NCT00556478)
Timeframe: 2 months
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Control | Distress | Sexual satisfaction | Interpersonal difficulty | |
| Double-Blind Active / Open-Label Active | 67.5 | 70.1 | 69.4 | 75.8 |
| Double-Blind Placebo / Open-Label Active | 24.7 | 33.8 | 27.3 | 42.9 |
Scores for perceived control over ejaculation, personal distress related to ejaculation, satisfaction with sexual intercourse and interpersonal difficulty related to ejaculation based on the subject PEP at month 3. Proportion of subjects with at least a 1 point category improvement in subject PEP domain scores from baseline to month 3. (NCT00556478)
Timeframe: 3 months
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Control | Distress | Sexual satisfaction | Interpersonal difficulty | |
| Double-Blind Active / Open-Label Active | 72.4 | 76.9 | 73.7 | 77.6 |
| Double-Blind Placebo / Open-Label Active | 24.1 | 36.7 | 36.7 | 59.5 |
1 trial available for prilocaine and Sensation Disorders
| Article | Year |
|---|---|
Improved sensory relearning after nerve repair induced by selective temporary anaesthesia - a new concept in hand rehabilitation.
Topics: Adult; Aged; Anesthetics, Local; Double-Blind Method; Female; Forearm; Hand; Humans; Learning; Lidoc | 2006 |
4 other studies available for prilocaine and Sensation Disorders
| Article | Year |
|---|---|
Trigeminal nerve injury associated with injection of local anesthetics: needle lesion or neurotoxicity?
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anesthetics, Local; Cartica | 2011 |
Topical lidocaine-prilocaine spray for the treatment of premature ejaculation: a proof of concept study.
Topics: Administration, Topical; Adult; Aerosols; Aged; Anesthetics, Local; Ejaculation; Erectile Dysfunctio | 2003 |
Nerve damage associated with inferior alveolar nerve blocks.
Topics: Adult; Aged; Anesthesia, Dental; Anesthetics, Local; Chorda Tympani Nerve; Dental Restoration, Perma | 1995 |
Permanent nerve involvement resulting from inferior alveolar nerve blocks.
Topics: Adult; Aged; Aged, 80 and over; Anesthesia, Dental; Anesthetics, Local; Causalgia; Female; Humans; I | 2000 |